At the Queen Elizabeth Hospital in Birmingham, neurosurgeons sometimes remove pieces of cerebral or cerebellar cortex for clinical reasons. With the patients' written consent, part of that tissue goes into ice-cold culture medium. It is chopped into cubes 350 micrometres a side and processed within half an hour. The next day the fragments sit in culture plates, still alive.

On those fragments, and on cells derived from blood, the group of Nicholas Barnes, a pharmacologist at the University of Birmingham, tried to switch off an inflammation trigger. The paper has 37 authors and appeared in the journal Brain online on 19 February 2026. The printed issue is October's, and the university's press release came with it.
The trigger is called P2X7. It is a receptor on the surface of immune cells. It opens when there is a lot of ATP outside the cell, the energy-carrying molecule that damaged cells spill after a blow. Once open, P2X7 activates the inflammasome, a protein complex that cuts and releases two inflammatory messengers, interleukin-1β and interleukin-18. In the brain the main source is microglia, the resident immune cells.

The authors' stated starting point is traumatic brain injury. It ranks among the major causes of death worldwide and has no approved drugs. After the initial impact, microglia activate and inflammation spreads the damage for days. That is the window a drug could use. In animal models P2X7 already has a role in this process. Evidence from human tissue was missing.
The team first made microglia-like cells from monocytes, white blood cells from healthy donors. After five to seven days in a cocktail of growth factors the cells carried typical microglial markers and engulfed myelin fragments. The team first primed them with a bacterial toxin, lipopolysaccharide. Then they added BzATP, a molecule that opens P2X7 more strongly than ATP. At the highest dose, cells from five donors released on average 2,688 picograms per millilitre of interleukin-1β and 282 of interleukin-18.

In a panel of 45 molecules measured in cells from three donors, interleukin-1β rose the most, almost two-hundredfold over baseline. With a reference blocker, A-804598, the rise shrank to about tenfold. Two experimental Janssen blockers, JNJ-54175446 and JNJ-55308942, curbed the release at nanomolar concentrations. The more potent one halved the response at about one nanomolar. An inflammasome inhibitor, MCC950, and a caspase-1 inhibitor, which blocks the cutting enzyme, worked as well. The pathway is the expected one.
Then came the slices of human brain. There too BzATP raised cytokines in step with the dose. P2X7 antagonists cut the release at concentrations the authors call pharmacologically relevant, close to those reachable in a patient's brain. The authors infer that blocking P2X7 in the central nervous system could limit inflammation after injury. It is a prediction. No patients were treated.
The release reposted by ScienceDaily on 7 October leads on Alzheimer's and Parkinson's. The paper does not study either disease. Its abstract, introduction and methods mention only brain injury and unspecified "neuroinflammatory pathologies". The release speaks of "live cultures of human brain cells", but the cells in the first part come from the blood of healthy donors. It speaks of repurposing existing drugs. The two Janssen compounds are experimental and have no marketing authorisation.

The release is also silent on industry. Ten authors work for Celentyx, a Birmingham pharmacology company, which is also listed as a funder alongside the UK Medical Research Council and the National Institute for Health and Care Research. The two experimental compounds were a gift from Janssen. Such ties are common in translational pharmacology. Readers still need them to weigh the promise.
The limits are those of in vitro and ex vivo work. The slices come from patients operated on for other reasons, not from injured brains. A slice kept in a dish for a day has no blood flow, no blood-brain barrier and none of the long course of a disease. The next step the team names is clinical trials in brain injury and other conditions with brain inflammation.

Potency of the three P2X7 antagonists tested in human monocyte-derived microglia: concentration halving interleukin-1β release. Nanomolar values computed in-house from the published pIC50. Chart produced by ScienceOnline from data in Cowley J. et al., Brain 2026, doi 10.1093/brain/awag068 (CC BY 4.0 licence).

References
Cowley J., Harrison N., Pegg A. et al., "P2X7 receptor-mediated IL-1β release by human brain tissue: the impact of CNS-penetrant potential therapeutics", Brain, 149, 10, 3614–3630, published online 19 February 2026, October 2026 issue, open access, CC BY 4.0 licence. doi: 10.1093/brain/awag068
University of Birmingham, press release reposted by ScienceDaily on 7 October 2026, "Drug Target Could Block Brain Inflammation Linked to Alzheimer's and Parkinson's" (used only as a lead).

*Board Member, SRSN (Roman Society of Natural Science)
Past Editor-in-Chief Italian Journal of Dermosurgery